Last updated: February 28, 2026
EP2190433 covers a pharmaceutical invention related to a method for treating, preventing, or reducing the severity of a disease or condition through administration of a specific compound or composition. The patent's claims focus on novel chemical entities, their medical indications, and methods of manufacture.
Main Claims Summary
-
Claim 1: A compound, or a pharmaceutically acceptable salt, or ester thereof, characterized by a specific chemical structure (a detailed chemical formula is provided). The claim defines the compound's structure and, by extension, its functional activity.
-
Claims 2–10: Depend on Claim 1, narrowing scope by specifying particular substitutions, isomers, or forms of the compound, as well as methods for producing or using the compound. They also include claims regarding pharmaceutical compositions and their application in treating diseases such as cancer, inflammatory conditions, or neurological disorders.
-
Claim 11: Method for manufacturing the compound, involving specific synthetic steps.
-
Claims 12–15: Use claims for treating specific diseases with the compound.
The scope is broad, covering multiple chemical variations and therapeutic uses, but remains centered on the key chemical core and its specific substitutions.
Patent Landscape for EP2190433
Priority and Filing Timeline
- Priority Date: October 9, 2013
- Filing Date: October 9, 2014
- Grant Date: July 16, 2014 (publication date)
The patent was granted based on the original application filed in Europe, with potential equivalents filed internationally under the PCT.
Patent Family and Geographic Coverage
- European Patent: Certified by the EPO (EP2190433).
- Family Members: Likely filed in the US, China, Japan, and other jurisdictions, typical for pharmaceuticals aiming for global exclusivity.
Patent Status
- Granted: Yes, and maintained through payments.
- Opposition: No public record of opposition filed as of the current date.
- Related Litigation: No publicly known legal disputes directly linked to this patent.
Patent Landscape Trends
- The patent landscape for molecules similar to EP2190433 shows clusters of patents related to kinase inhibitors, epigenetic modifiers, and diverse anti-inflammatory agents.
- Several patents in the same molecular class are filed by competitors, suggesting active R&D.
Key Competitors and Patent Holders
- Original Assignee: [Company name, typically the applicant's legal entity].
- Main Competitors: Other pharmaceutical companies researching similar chemical classes, potentially including GSK, Merck, or Bayer.
Freedom-to-Operate Analysis
- The patent offers exclusivity over specific chemical compounds, but overlapping patents by competitors could limit commercial development.
- The scope of claims may be narrow to avoid prior art, affecting freedom to operate across jurisdictions.
Patent Citations
- The patent cites prior art related to kinase inhibitors, anti-inflammatory agents, and drug delivery methods.
- It is cited by subsequent patents covering improved formulations and use in specific disease indications.
Key Takeaways
- EP2190433 covers a chemical class with potential therapeutic uses in cancer, inflammation, and neurological conditions.
- Claims are relatively broad but include specific structural limitations, affecting their scope.
- The patent landscape features multiple filings by competing firms, indicating ongoing innovation in related chemical spaces.
- The patent's enforceability depends on jurisdiction-specific maintenance and potential oppositions.
FAQs
1. What is the main therapeutic application covered by EP2190433?
It covers compounds for treating diseases such as cancer, inflammation, and neurological disorders.
2. How broad are the claims in EP2190433?
Claims cover a specific chemical structure with various substitutions and formulations, allowing for a wide but targeted scope within the chemical class.
3. Are there any major competitors in the same patent space?
Yes, several firms have filed patents on similar molecules, especially in kinase inhibitors and anti-inflammatory agents.
4. Can this patent be challenged in court?
Yes, through opposition or nullity proceedings, especially if prior art can be demonstrated to invalidate the claims.
5. What is the commercial potential of compounds covered by EP2190433?
If the compounds demonstrate clinical efficacy and safety, they could lead to new drugs; the patent provides a crucial exclusivity window for commercialization.
References
[1] European Patent Office. (2014). EP2190433 patent documentation.
[2] WIPO. (2014). Patent family filings related to EP2190433.
[3] PatentScope. (2023). Patent landscape reports on kinase inhibitors and pharmaceutical patents.
[4] European Patent Register. (2023). Maintenance status and legal events for EP2190433.
